 |
| 01-Apr-13 | Reiterated |
MLV & Co |
Buy |
$16 → $18.50 |
|
| 30-Aug-12 | Initiated |
Stifel Nicolaus |
Hold |
|
|
| 05-Jan-12 | Initiated |
Rodman & Renshaw |
Mkt Outperform |
$8 |
|
| 14-Mar-11 | Reiterated |
Barclays Capital |
Equal Weight |
$2 → $4 |
|
| 28-Feb-11 | Upgrade |
Canaccord Genuity |
Hold → Buy |
$4.50 → $8 |
|
| 09-Nov-10 | Initiated |
MLV Capital |
Buy |
$8.50 |
|
| 26-Aug-10 | Initiated |
Morgan Joseph |
Buy |
$6 |
|
| 10-May-10 | Upgrade |
Roth Capital |
Hold → Buy |
$4 |
|
| 19-Feb-10 | Initiated |
RBC Capital Mkts |
Sector Perform |
$5 |
|
| 17-Feb-10 | Downgrade |
Roth Capital |
Buy → Hold |
$4 |
|
| 05-Nov-09 | Upgrade |
Roth Capital |
Hold → Buy |
$2 → $4 |
|
| 27-Feb-09 | Downgrade |
Wachovia |
Mkt Perform → Underperform |
|
|
| 27-Feb-09 | Downgrade |
Roth Capital |
Buy → Hold |
$11 → $2 |
|
| 27-Feb-09 | Downgrade |
Rodman & Renshaw |
Mkt Outperform → Mkt Perform |
|
|
| 27-Feb-09 | Downgrade |
RBC Capital Mkts |
Outperform → Sector Perform |
|
|
| 27-Feb-09 | Downgrade |
Lazard Capital |
Buy → Hold |
|
|
| 01-Dec-08 | Initiated |
Banc of America Sec |
Neutral |
|
|
| 20-Nov-08 | Reiterated |
Rodman & Renshaw |
Mkt Outperform |
|
|
| 06-Nov-08 | Initiated |
Wachovia |
Mkt Perform |
|
|
| 02-Jun-08 | Initiated |
Susquehanna Financial |
Positive |
$16 |
|
|
|
| 15-May-13 06:30PM | Synta Announces Presentations at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting Business Wire |
| 14-May-13 10:16AM | Synta Is a Run-Up Trade Into ASCO Lung Cancer Data at TheStreet |
| 10-May-13 05:15PM | 3 Horrendous Health-Care Stocks This Week at Motley Fool |
| 07:00AM | Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin at TheStreet |
| 08-May-13 04:35PM | Synta Pharmaceuticals Becomes Oversold (SNTA) at TheStreet -13.38% |
| 07-May-13 01:40PM | Why Synta Pharmaceuticals Shares Sank at Motley Fool -15.47% |
| 06-May-13 10:24AM | SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events EDGAR Online |
| 04-May-13 01:04PM | SYNTA PHARMACEUTICALS CORP Financials EDGAR Online Financials |
| 30-Apr-13 04:30PM | Synta Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 10:00AM | Synta Pharmaceuticals Corp. Earnings Call scheduled for 10:00 am ET today CCBN |
| 07:07AM | Q1 2013 Synta Pharmaceuticals Corp. Earnings Release - Before Market Open CCBN |
| 06:52AM | InPlay: Synta Pharma misses by $0.03; provides clinical update for GALAXY-1 Phase 2b/3 trial Briefing.com |
| 06:45AM | Synta Provides Clinical Updates and Reports First Quarter 2013 Financial Results Business Wire |
| 29-Apr-13 11:14PM | SYNTA PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 07:07PM | Synta Pharmaceuticals Earnings Preview: Get Ahead of the Analysts at Wall St. Cheat Sheet |
| 26-Apr-13 08:15AM | Biotech Stock Mailbag: ASCO, Sarepta, Cel-Sci and Hate Mail! at TheStreet |
| 22-Apr-13 07:46AM | Synta says first patients treated in GALAXY-2 trial evaluating Ganetespib theflyonthewall.com |
| 07:45AM | Synta Announces First Patients Treated in Pivotal GALAXY-2 Trial Evaluating Ganetespib in Advanced Non-Small Cell Lung Cancer Business Wire |
| 16-Apr-13 07:45AM | Synta to Host Conference Call and Webcast of First Quarter 2013 Financial Results on April 30, 2013 Business Wire |
| 05-Apr-13 04:15PM | Synta Announces Presentations at the 2013 Annual Meeting of the American Association of Cancer Research Business Wire +8.00% |
| 02-Apr-13 02:57PM | Tackling Cancer: Melanoma's Biggest Current & Upcoming Players at Motley Fool |
| 01-Apr-13 03:33PM | BlackBerry Will Underperform and 4 More Analyst Notes to Looks At at Wall St. Cheat Sheet |
| 01:46AM | SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan EDGAR Online |
| 29-Mar-13 11:59AM | Tokai promotes Jodie Morrison to CEO at bizjournals.com |
| 25-Mar-13 11:26AM | Synta's Slump On Shelf Registration Provides Entry Point Ahead Of ASCO at Seeking Alpha |
| 19-Mar-13 01:04PM | SYNTA PHARMACEUTICALS CORP Financials EDGAR Online Financials |
| 16-Mar-13 07:32PM | New Star Analyst Rankings for Synta Pharmaceuticals Corp. StarMine |
| 15-Mar-13 07:41PM | New Star Analyst Rankings for Synta Pharmaceuticals Corp. StarMine |
| 11:01AM | Steven Quay, CEO of Atossa Genetics, Inc. (ATOS), Interviews with The Wall Street Transcript Wall Street Transcript |
| 14-Mar-13 04:02PM | Synta Pharma announces new offering, trades lower AP |
| 02:50PM | Why Synta Pharmaceuticals Shares Stumbled at Motley Fool |
| 12:10PM | Synta Pharmaceuticals Management Discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha |
| 10:00AM | Q4 and Year-End 2012 Synta Pharmaceuticals Corp. Earnings Call scheduled for 10:00 am ET today CCBN |
| 10:00AM | Hibbett Sports, Inc. Earnings Call scheduled for 10:00 am ET today CCBN |
| 09:49AM | Q4 and Year-End 2012 Synta Pharmaceuticals Corp. Earnings Call scheduled for 10:00 am ET today CCBN |
| 07:52AM | Synta Pharma sees cash resources sufficient to fund operations into 2Q14 at theflyonthewall.com |
| 07:50AM | Synta Provides Company Updates and Reports Fourth Quarter and Year-End 2012 Financial Results Business Wire |
| 07:40AM | Synta Pharmaceuticals files $300M mixed securities shelf theflyonthewall.com |
| 07:22AM | SYNTA PHARMACEUTICALS CORP Files SEC form 10-K, Annual Report EDGAR Online |
| 07:07AM | Q4 2012 Synta Pharmaceuticals Corp. Earnings Release - Before Market Open CCBN |
| 13-Mar-13 05:18PM | InPlay: Synta Pharma announces appointment of Sumant Ramachandra, M.D., Ph.D. as President, Research and Development Briefing.com |
| 05:00PM | SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
| 04:15PM | Synta Announces Appointment of Sumant Ramachandra, M.D., Ph.D. as President, Research and Development Business Wire |
| 12-Mar-13 06:00PM | Synta Pharmaceuticals Corp. Presents at Barclays Global Healthcare Conference, Mar-12-2013 03:45 PM at Seeking Alpha |
| 11-Mar-13 08:15AM | Outlook for Diagnostic Substances Industry Marketwire |
| 08-Mar-13 07:00PM | 5 Reasons to Worry About Next Week at Motley Fool |
| 05:04PM | SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online |
| 03:15AM | George Zavoico: Biotech Stocks That Deserve A Closer Look at Seeking Alpha |
| 06-Mar-13 01:24PM | Synta plans to enroll first patient in lung cancer trial at bizjournals.com |
| 05-Mar-13 09:28AM | Trius Therapeutics: New MSRA Treatment Could Bring Billions In Revenues at Seeking Alpha +7.34% |
| 28-Feb-13 10:01AM | Synta Pharmaceuticals' Subgroup Selection Strategy Is A Set-Up For Success at Seeking Alpha |
| 25-Feb-13 07:15AM | Synta to Host Conference Call and Webcast of Fourth Quarter and Year-End 2012 Financial Results on March 14, 2013 Business Wire |
| 13-Feb-13 10:06AM | Why Synta Pharmaceuticals Is Poised to Plunge at Motley Fool |
| 11-Feb-13 08:00AM | Synta to Present at Upcoming Conferences Business Wire |
| 30-Jan-13 10:10AM | Insiders Bullish on Certain Holdings of IWC at Forbes |
| 28-Jan-13 08:20AM | Mergers and Acquisitions on the Rise in 2013 as Big Pharma Companies Hold Record Amounts of Cash on Hand Marketwire |
| 24-Jan-13 03:31PM | ARIAD prices $300M stock offering to support launch of leukemia drug at bizjournals.com |
| 23-Jan-13 09:18AM | Insiders Love These 3 Highly Shorted Healthcare Stocks at Seeking Alpha |
| 15-Jan-13 12:09PM | Synta: Share Price Not Reflecting Ganetespib Value Proposition at Seeking Alpha |
| 28-Dec-12 11:41AM | Here's What Graham Capital Management Has Been Buying at Motley Fool |
| 11:37AM | Molecular Therapeutics in Oncology Driving U.S. Biotech Valuations: New Diagnostic Based Therapies Create Defensive Fiscal Cliff Resistant Portfolio Strategy Wall Street Transcript |
| 20-Dec-12 04:12PM | SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E EDGAR Online |
| 14-Dec-12 08:33PM | 3 Humongous Health-Care Stocks This Week at Motley Fool |
| 13-Dec-12 05:07PM | SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St EDGAR Online |
| 02:59PM | Synta to raise $60M through direct stock offering at bizjournals.com |
| 12:30PM | Regeneron Pharmaceuticals and More Big Movers in Healthcare on December 13, 2012 at Investopedia |
| 12:26PM | Synta Pharma: Poised For A Breakout With 4 Near-Term Catalysts at Seeking Alpha |
| 07:51AM | InPlay from Briefing.com Briefing.com |
| 07:31AM | InPlay: Synta Pharma entered into common stock purchase agreements with members of its Board of Directors and institutional investors for the sale of 7 mln shares of its common stock; shares were priced at $8.60 Briefing.com |
| 07:30AM | Synta Pharmaceuticals Announces $60 Million Registered Direct Common Stock Offering Business Wire |
| 12-Dec-12 04:05PM | InPlay: Synta Pharma announces stock offering Briefing.com |
| 04:05PM | Synta Pharmaceuticals Announces Proposed Registered Direct Offering of Common Stock Business Wire |
| 11-Dec-12 08:45AM | Tuesday's Small-Cap Biopharma Catalyst Trade List at Seeking Alpha +10.69% |
| 07:12AM | Synta Pharma: Poised For A Breakout With 4 Near Term Catalysts Thomson Reuters ONE |
| 27-Nov-12 07:45AM | Synta to Present at the Deutsche Bank 2012 dbAccess BioFEST Business Wire |
| 26-Nov-12 07:45AM | Interim Results of the Phase 2b/3 GALAXY Trial to be Presented at the Fifth Asia Pacific Lung Cancer Conference Business Wire |
| 14-Nov-12 08:10AM | 5 Healthcare Companies With Significant Recent Insider Buying (Part IV) at Seeking Alpha |
| 10-Nov-12 01:04PM | SYNTA PHARMACEUTICALS CORP Financials EDGAR Online Financials |
| 09-Nov-12 08:15AM | Synta to Present at the Lazard Capital Markets 9th Annual Healthcare Conference Business Wire |
| 07-Nov-12 09:36AM | New Star Analyst Rankings for Synta Pharmaceuticals Corp. StarMine |
| 08:15AM | Interim Results of the Phase 2b GALAXY Trial to be Presented at the Chemotherapy Foundation Symposium Business Wire |
| 06-Nov-12 05:00PM | Synta Pharmaceuticals Management Discusses Q3 2012 Results - Earnings Call Transcript at Seeking Alpha |
| 10:00AM | Synta Pharmaceuticals Corp. Earnings Call scheduled for 10:00 am ET today CCBN |
| 09:46AM | Synta Pharmaceuticals Corp. Earnings Call scheduled for 10:00 am ET today CCBN |
| 07:23AM | InPlay: Synta Pharma beats by $0.01; Phase 3 ganetespib lung cancer trial initiating, final results expected 2014 Briefing.com |
| 07:15AM | Synta Provides Clinical Update and Reports Third Quarter 2012 Financial Results Business Wire |
| 07:07AM | Q3 2012 Synta Pharmaceuticals Corp. Earnings Release - Before Market Open CCBN |
| 06:06AM | SYNTA PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 05-Nov-12 04:01PM | Investments In The Fight Against Cancer: The Analysts' Choices at Seeking Alpha |
| 24-Oct-12 07:00AM | Synta to Host Third Quarter 2012 Conference Call on November 6, 2012 Business Wire |
| 08-Oct-12 06:07PM | Winners Of ESMO 2012 at Seeking Alpha |
| 03-Oct-12 04:24PM | On The Fly: Closing Wrap theflyonthewall.com |
| 08:32AM | Biotech Industry Applauds Introduction of the High Technology Small Business Research Incentives Act Marketwire |
| 02-Oct-12 08:31AM | Ocwen Financial Teams Up With IBM and 4 Stocks Riding 52-Week Highs at Wall St. Cheat Sheet |
| 08:27AM | Biotech Industry Applauds Introduction of the High Technology Small Business Research Incentives Act Marketwire |
| 08:25AM | Biotech Industry Applauds Introduction of the High Technology Small Business Research Incentives Act Marketwire |
| 08:20AM | Biotech Industry Applauds Introduction of the High Technology Small Business Research Incentives Act Marketwire |
| 01-Oct-12 10:56PM | 2-Star Stocks Poised to Plunge: Synta Pharmaceuticals? at Motley Fool +23.49% |
| 05:50PM | Goldman Sachs Upbeat About Commodities and 4 Hot Stocks Buzzing on The Street at Wall St. Cheat Sheet |
| 04:46PM | SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online |
|
|
| Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug candidates in clinical trials for treating multiple types of cancer and various drug candidates in the preclinical stage of development. Its oncology product pipeline includes Ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trials for the treatment of second-line advanced adenocarcinoma non-small cell lung cancer (NSCLC) with adenocarcinoma histology; in Phase IIb/III clinical trials for the treatment of adenocarcinoma NSCLC; in Phase II clinical trials for NSCLC patients whose tumors have a genetic profile characterized by rearrangement of the ALK gene and patients with newly diagnosed HER2+ and triple-negative metastatic breast cancer; in Phase II clinical trials for the treatment of breast cancer, lung cancer, acute myeloid leukemia (AML), and rectal cancer; and in Phase I/II clinical trials for treating mesothelioma and multiple myeloma, as well as has completed Phase II clinical trials for treating NSCLC. The company's product pipeline also comprises additional Hsp90 inhibitors, which are in preclinical development stage for cancer; Elesclomol, a mitochondria-targeting agent that is in Phase I/II clinical trials for ovarian cancer and Phase I clinical trials for AML; and STA-9584, a vascular disrupting agent in preclinical development stage for prostate cancer. Its product pipeline for inflammatory diseases includes CRACM ion channel inhibitors in preclinical development stage for autoimmune diseases, respiratory conditions, and transplantation; and IL-12/23 inhibitors in lead optimization stage for autoimmune diseases. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Gollust Keith R | Director | Jan 23 | Option Exercise | 8.66 | 114,250 | 989,603 | 316,255 | Jan 24 04:59 PM | | Kovner Bruce | Director | Nov 14 | Buy | 6.95 | 10,500 | 73,009 | 947,700 | Nov 14 06:45 PM | | Kovner Bruce | Director | Nov 14 | Buy | 6.95 | 10,500 | 73,009 | 947,700 | Nov 14 06:48 PM | | Bahcall Safi R | President and CEO | Nov 12 | Buy | 7.12 | 10,000 | 71,200 | 2,373,135 | Nov 13 09:06 AM | | Kovner Bruce | Director | Nov 12 | Buy | 6.89 | 27,200 | 187,449 | 937,200 | Nov 14 06:48 PM | | Kovner Bruce | Director | Nov 12 | Buy | 6.89 | 27,200 | 187,449 | 937,200 | Nov 14 06:45 PM | | Kovner Bruce | Director | Jun 29 | Buy | 5.45 | 910,000 | 4,959,318 | 6,816,048 | Jul 02 04:53 PM | | Gollust Keith R | Director | Jun 29 | Buy | 5.35 | 150,000 | 801,900 | 1,827,967 | Jul 02 02:45 PM | | Bahcall Safi R | President and CEO | Jun 29 | Buy | 5.34 | 10,000 | 53,370 | 2,343,135 | Jul 02 08:53 AM | | Vukovic Vojo | SVP, Chief Medical Officer | Jun 29 | Buy | 5.59 | 3,000 | 16,755 | 25,249 | Jul 02 08:53 AM | | Rieder Wendy E | VP, IP and Legal, Gen. Counsel | Jun 18 | Option Exercise | 2.49 | 7,170 | 17,853 | 26,993 | Jun 20 04:08 PM | | Rieder Wendy E | VP, IP and Legal, Gen. Counsel | Jun 18 | Sale | 6.00 | 7,170 | 43,020 | 19,823 | Jun 20 04:08 PM | | Rieder Wendy E | VP, IP and Legal, Gen. Counsel | Jun 04 | Option Exercise | 2.49 | 7,170 | 17,853 | 26,993 | Jun 06 04:23 PM | | Rieder Wendy E | VP, IP and Legal, Gen. Counsel | Jun 04 | Sale | 5.50 | 7,170 | 39,435 | 19,823 | Jun 06 04:23 PM |
|
|
|
|
|
|
